| dc.creator |
GÜMÜŞAY, ÖZGE |
|
| dc.creator |
AFŞAR, Barış |
|
| dc.creator |
Bilgetekin, Irem |
|
| dc.creator |
ÇETİN, Bülent |
|
| dc.creator |
ÖZET, AHMET |
|
| dc.creator |
ÜNER, AYTUĞ |
|
| dc.creator |
IŞIK GÖNÜL, İPEK |
|
| dc.date |
2021-04-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:14:35Z |
|
| dc.date.available |
2021-12-03T11:14:35Z |
|
| dc.identifier |
055d814e-cc98-45bf-a7a8-c42997f1df64 |
|
| dc.identifier |
10.4103/jcrt.jcrt_372_18 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/055d814e-cc98-45bf-a7a8-c42997f1df64/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/89737 |
|
| dc.description |
Objective: Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study evaluates ezrin expression in sunitinib-treated metastatic clear cell renal cell carcinoma (ccRCC) patients and elucidates its role as a possible marker for survival. Materials and Methods: The expression of ezrin was measured by immunohistochemistry in 80 patients with ccRCC treated by first-line sunitinib between January 2007 and June 2012. Kaplan-Meier curves and log-rank tests were used for analysis of progression-free survival and overall survival (OS), and a multivariate Cox proportional hazard model was employed to identify factors with an independent effect on the survival. Results: In multivariate analysis, liver metastasis (P = 0.018; hazard ratio [HR]: 3.707 (1.257-10.931) and overexpression of ezrin (P = 0.006; HR: 2.993 (1.373-6.523 95% confidence interval) were remained significant factors influencing OS. Overexpression of ezrin in the patients who had progressed in the first 3 months was higher than in the patients who had progressed after 3 months (P = 0.003). The median OS was longer in patients with low levels of ezrin expression (27 months) compared to patients overexpressing ezrin (12 months) (P = 0.001). Conclusion: This is the first study in the literature showing that ezrin status is related with prognosis in patients with metastatic ccRCC. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib |
|
| dc.type |
info:eu-repo/semantics/article |
|